PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 1998BMJ6,743 citationsOpen Access

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

UGUK Prospective Diabetes Study GroupOxford Centre for Diabetes, Endocrinology and Metabolism

Key Result

Tight blood pressure control reduced the risk of any diabetes-related endpoint by 24% compared to less tight control in patients with type 2 diabetes.

Study Design

Type

RCT (n=1,148)

Blinding

null

Randomization

null

Multicenter

Yes

Structured PICO

Does tight control of blood pressure prevent macrovascular and microvascular complications in hypertensive patients with type 2 diabetes?

P
Population
Hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg)
I
Intervention
Tight control of blood pressure aiming at <150/85 mm Hg (with the use of captopril or atenolol as main treatment)
C
Comparator
Less tight control aiming at a blood pressure of <180/105 mm Hg (avoiding angiotensin converting enzyme inhibitors and β blockers)
O
Outcome
Time to the occurrence of a first clinical end point related to diabetes, death related to diabetes, and death from all causescomposite

Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of diabetes-related deaths, macrovascular complications like stroke, and microvascular complications.

Main Result

Effect estimate: RR 0.76 (95% CI 0.62-0.92)

Absolute Event Rate: 11% vs 14%

p-value: p=0.0046

Limitations

  • Limited to hypertensive patients with type 2 diabetes
  • Results may not generalize to populations without diabetes or with different comorbidities

Abstract

Abstract Objective: To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes. Design: Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a β blocker atenolol as main treatment) with less tight control aiming at a blood pressure of <180/105 mm Hg. Setting: 20 hospital based clinics in England, Scotland, and Northern Ireland. Subjects: 1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years. Main outcome measures: Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography. Results: Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P<0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures. Conclusion: Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

UK Prospective Diabetes Study Group (1998) conducted an RCT in Type 2 diabetes (n=1,148). Captopril or Atenolol vs. Less tight control aiming at < 180/105 mm Hg was evaluated on Any clinical end point related to diabetes (fatal and non-fatal) (RR 0.76, 95% CI 0.62-0.92, p=0.0046). Tight blood pressure control reduced the risk of any diabetes-related endpoint by 24% compared to less tight control in patients with type 2 diabetes.

synapsesocial.com/papers/6966d319fa5be6f252f7bc97https://doi.org/10.1136/bmj.317.7160.703
Ask AI
Helpful
Bookmark
Share
View Full Paper